Valuation : ALLOVIRPAR

Market Cap 4.92Cr 4.25Cr 4Cr 3.64Cr 6.81Cr 464.88Cr 6.86Cr 47Cr 18Cr 237.68Cr 18Cr 18Cr 780.76Cr P/E 2023
-0.37x
P/E 2024 -0.82x
Enterprise Value -6.91Cr -5.96Cr -5.61Cr -5.11Cr -9.56Cr -652.54Cr -9.63Cr -66Cr -26Cr -333.63Cr -26Cr -25Cr -1.1TCr EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
-
Yield 2023 *
-
Yield 2024 -
1 day+1.40%
Current month-59.63%
Current year-59.63%
3 years 3.95
Extreme 3.95
76.24
5 years 3.95
Extreme 3.95
607.43
10 years 3.95
Extreme 3.95
1,126.08

Financials

2023 2024
Net sales - -
Net income -19Cr -16Cr -15Cr -14Cr -26Cr -1.8TCr -27Cr -183.21Cr -71Cr -919.66Cr -72Cr -70Cr -3.02TCr -5.88Cr -5.07Cr -4.78Cr -4.35Cr -8.13Cr -555.16Cr -8.19Cr -57Cr -22Cr -283.84Cr -22Cr -22Cr -932.39Cr
Net Debt -16Cr -14Cr -13Cr -12Cr -22Cr -1.48TCr -22Cr -150.59Cr -58Cr -755.92Cr -59Cr -57Cr -2.48TCr -12Cr -10Cr -9.61Cr -8.76Cr -16Cr -1.12TCr -16Cr -113.81Cr -44Cr -571.3Cr -44Cr -43Cr -1.88TCr
Logo ALLOVIRPAR
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
Employees
6
Sector
-
Date Price Change
03/26/03 $3.960 +1.02%
01/26/01 $3.920 -2.97%
31/26/31 $4.040 +0.25%
28/26/28 $4.030 -1.71%
27/26/27 $4.100 +0.49%
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. ALVR Stock